Paper 82 - PHASE I/II STUDY OF THE TGF-BETA-TRAP ENHANCED ONCOLYTIC ADENOVIRUS, ADAPT-001, WITH AND WITHOUT AN IMMUNE CHECKPOINT INHIBITOR FOR SARCOMA PATIENTS

Author(s)

• 

  Anthony P. Conley, MD

  Associate Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States

  Slides

Co-Author(s)

• VR

  Vinod Ravi, MD, MBA

  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Christina Roland, MD, MS (she/her/hers)

  Associate Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• TR

  Tony Reid, MD, PhD

  EpicentRx
  San Diego, California, United States
• 

  Christopher Larson, MD, PhD

  Vice President of Viral Therapy. Sarcoma medical oncologist.
  EpicentRx. UCSD.
  La Jolla, California, United States
• SC

  Scott Caroen, BS

  EpicentRx
  San Diego, California, United States
• JW

  Jeannie Williams, RN, MSN, AOCNS

  Director, Clinical Operations
  EpicentRx
  Fairfax Station, Virginia, United States
• BO

  Bryan Oronsky, MD, PhD

  EpicentRx
  San Diego, California, United States
• MS

  Meaghan Stirn, MBA

  EpicentRx
  San Diego, California, United States
• NA

  Nacer Abrouk, PhD

  Clinical Trial Innovations
  San Diego, California, United States
• EB

  Erica Burbano, BS

  EpicentRx
  San Diego, California, United States
• LB

  Lucy Boyce Kennedy, MD

  Cleveland Clinic
  Cleveland, Ohio, United States
• 

  Santosh Kesari, MD, PhD

  Chair and Professor
  Providence Saint John's Health Center
  Santa Monica, California, United States